23 / 35
Clinical applicability and cost of a 46-gene panel:
retrospective validation and prospective audit in the
UK National Health Service
•
46-gene hotspot cancer panel assay
•
351 patients ( 108 NSCLC, 88 colorectal and 109 melanoma)
•
Median TAT 7 working days
•
A locally actionable mutation (available targeted treatment or clinical trial)
35% but targeted treatment only 15%
•
At a cost of £339 per patient, the panel was less expensive locally than
performing more than 2 o 3 single gene tests
Hamblin A et al. PLOS Medicine 2017